70765
document
MDMA-assisted therapy : A new treatment model for social anxiety in autistic adults . The first study of 3,4-methylenedioxymethamphetamine ( MDMA ) -assisted therapy for the treatment of social anxiety in autistic adults commenced in the spring of 2014 . The search for psychotherapeutic options for autistic individuals is imperative considering the lack of effective conventional treatments for mental health diagnoses that are common in this population . Serious Adverse Events ( SAEs ) involving the administration of MDMA in clinical trials have been rare and non-life threatening . To date , MDMA has been administered to over 1133 individuals for research purposes without the occurrence of unexpected drug-related SAEs that require expedited reporting per FDA regulations . Now that safety parameters for limited use of MDMA in clinical settings have been established , a case can be made to further develop MDMA-assisted therapeutic interventions that could support autistic adults in increasing social adaptability among the typically developing population . As in the case with classic hallucinogens and other psychedelic drugs , MDMA catalyzes shifts toward openness and introspection that do not require ongoing administration to achieve lasting benefits . This infrequent dosing mitigates adverse event frequency and improves the risk/benefit ratio of MDMA , which may provide a significant advantage over medications that require daily dosing . Consequently , clinicians could employ new treatment models for social anxiety or similar types of distress administering MDMA on one to several occasions within the context of a supportive and integrative psychotherapy protocol .
70766
Intervention_Physical
MDMA-assisted therapy
70767
Intervention_Pharmacological
3,4-methylenedioxymethamphetamine ( MDMA ) -assisted therapy
70768
Intervention_Pharmacological
MDMA
70769
Intervention_Pharmacological
MDMA
70770
Intervention_Pharmacological
MDMA
70771
Intervention_Physical
MDMA-assisted therapeutic interventions
70772
Intervention_Pharmacological
MDMA
70773
Intervention_Pharmacological
MDMA
70774
Intervention_Pharmacological
MDMA
70775
Outcome_Adverse-effects
Serious Adverse Events ( SAEs )
70776
Outcome_Adverse-effects
unexpected drug-related SAEs
70777
Outcome_Mental
social adaptability
70778
Outcome_Mental
openness and introspection
70779
Outcome_Adverse-effects
adverse event frequency
70780
Outcome_Physical
the risk/benefit ratio of MDMA
70781
Outcome_Mental
social anxiety
70782
Participant_Condition
social anxiety in autistic
70783
Participant_Condition
social anxiety in autistic adults commenced in the spring of 2014
70784
Participant_Condition
MDMA has been administered
70785
Participant_Sample-size
1133 individuals